{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:48:36Z","timestamp":1792093716550,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03591-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:29:43Z","timestamp":1779434983000},"page":"3535-3551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-221X","authenticated-orcid":false,"given":"Neil","family":"Hawkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-4465","authenticated-orcid":false,"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-2042","authenticated-orcid":false,"given":"Marisa","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7646-9460","authenticated-orcid":false,"given":"Juliette","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-4406","authenticated-orcid":false,"given":"Richard","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-4743","authenticated-orcid":false,"given":"Marius","family":"Sieverding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4344-2822","authenticated-orcid":false,"given":"Piotr","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Scherzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Danchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-0768","authenticated-orcid":false,"given":"Laure","family":"Dupont-Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"3591_CR1","unstructured":"US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention#:~:text=Today%2C%20the%20U.S.%20Food%20and%20Drug%20Administration,reduce%20the%20risk%20of%20sexually%20acquired%20HIV. Published December 20, 2021. Accessed July 9, 2025."},{"key":"3591_CR2","unstructured":"European Commission. Public Health - Union Register of medicinal products for human use. Apretude (cabotegravir). https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1760.htm. Accessed January 29, 2026."},{"key":"3591_CR3","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779\u201389.","journal-title":"Lancet"},{"key":"3591_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595\u2013608.","journal-title":"N Engl J Med"},{"key":"3591_CR5","unstructured":"Yeztugo [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2025."},{"key":"3591_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392:1261\u201376.","journal-title":"N Engl J Med"},{"key":"3591_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179\u201392.","journal-title":"N Engl J Med"},{"key":"3591_CR8","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.chest.2020.03.013","volume":"158","author":"EC Zabor","year":"2020","unstructured":"Zabor EC, Kaizer AM, Hobbs BP. Randomized controlledt trials. Chest. 2020;158:S79-87.","journal-title":"Chest"},{"key":"3591_CR9","unstructured":"Cochrane. Evidence synthesis - what is it and why do we need it? https:\/\/www.cochrane.org\/news\/evidence-synthesis-what-it-and-why-do-we-need-it. Published May 4, 2023. Accessed October 22, 2025."},{"key":"3591_CR10","unstructured":"Langlois \u00c9V, Daniels K, Akl EA, et al. Langlois \u00c9V, Daniels K, Akl EA, eds. Evidence Synthesis for Health Policy and Systems: A Methods Guide. Geneva: World Health Organization; 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569585\/. Accessed May 28, 2025."},{"key":"3591_CR11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s40121-025-01172-9","volume":"14","author":"N Hawkins","year":"2025","unstructured":"Hawkins N, O\u2019Brian P, Thompson J, et al. Indirect treatment comparison of long-acting injectable cabotegravir as pre-exposure prophylaxis when compared with no pre-exposure prophylaxis for HIV prevention. Infect Dis Ther. 2025;14:1739\u201353.","journal-title":"Infect Dis Ther"},{"key":"3591_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"E O Murchu","year":"2022","unstructured":"O Murchu E, Marshall L, Teljeur C, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12:e048478.","journal-title":"BMJ Open"},{"key":"3591_CR13","unstructured":"Huic M, Reinsperger I. Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient\/social, ethical and legal elements. AIHTA Project Report No.: 152; 2023. Vienna: HTA Austria \u2013 Austrian Institute for Health Technology Assessment GmbH. https:\/\/eprints.aihta.at\/1436\/1\/HTA-Projektbericht_Nr.152.pdf. Accessed October 22, 2025."},{"key":"3591_CR14","unstructured":"(CRD) CfRaD. Systematic Reviews. York Publishing Services Ltd; 2009."},{"key":"3591_CR15","unstructured":"Apretude [summary of product characteristics]. Torrile, Italy: GSK. 2025."},{"key":"3591_CR16","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","volume":"12","author":"MG Sension","year":"2023","unstructured":"Sension MG, Brunet L, Hsu RK, et al. Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort. Infect Dis Ther. 2023;12:2807\u201317.","journal-title":"Infect Dis Ther"},{"key":"3591_CR17","unstructured":"Ramgopal M, Brown C, Frick A, et al. Real-world use of cabotegravir long-acting for pre-422 exposure prophylaxis (PrEP): data from Trio Health cohort. Presented at: IDWeek; October 16\u201319, 2024; Los Angeles, CA."},{"key":"3591_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/jrsm.1187","volume":"7","author":"N Hawkins","year":"2016","unstructured":"Hawkins N, Scott DA, Woods B. \u2018Arm-based\u2019 parameterization for network meta-analysis. Res Synth Methods. 2016;7:306\u201313.","journal-title":"Res Synth Methods"},{"key":"3591_CR19","unstructured":"Martyn P. JAGS: a program for analysis of bayesian graphical models using Gibbs sampling. Presented at: 3rd International Workshop on Distributed Statistical Computing (DSC 2003); March 20\u201322, 2003; Vienna, Austria."},{"key":"3591_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434\u201355.","journal-title":"J Comput Graph Stat"},{"issue":"6","key":"3591_CR21","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2468-2667(22)00106-2","volume":"7","author":"H Jourdain","year":"2022","unstructured":"Jourdain H, de Gage SB, Desplas D, Dray-Spira R. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. Lancet Public Health. 2022;7(6):e529\u201336.","journal-title":"Lancet Public Health"},{"key":"3591_CR22","unstructured":"HIV.gov. Long-Acting HIV Prevention Tools. January 31, 2025. Available at: https:\/\/www.hiv.gov\/hiv-basics\/hiv-prevention\/potential-future-options\/long-acting-prep. Accessed January 29, 2026."},{"issue":"6","key":"3591_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/15248399211053584","volume":"23","author":"NA Pilgrim","year":"2022","unstructured":"Pilgrim NA, Evans TM, Czarnogorski M. A layer plus approach to implementation research and collaboration for long-acting injectable preexposure prophylaxis for HIV prevention. Health Promot Pract. 2022;23(6):912\u20135.","journal-title":"Health Promot Pract"},{"issue":"1","key":"3591_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","volume":"21","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, et al. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Serv Res. 2021;21(1):255.","journal-title":"BMC Health Serv Res"},{"issue":"S1","key":"3591_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26282","volume":"27","author":"N Nguyen","year":"2024","unstructured":"Nguyen N, Lane B, Golub SA, et al. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project. J Int AIDS Soc. 2024;27(S1):e26282.","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 2(Suppl 2","key":"3591_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26497","volume":"28","author":"KL Nelson","year":"2025","unstructured":"Nelson KL, Evans Cooper T, Lawson Y, et al. Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study. J Int AIDS Soc. 2025;28(Suppl 2(Suppl 2)):e26497.","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 4","key":"3591_CR27","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. Clin Infect Dis. 2022;75(Suppl 4):S541\u20138.","journal-title":"Clin Infect Dis"},{"key":"3591_CR28","doi-asserted-by":"crossref","unstructured":"Boles J, Elliot E, Fox D, et al. Cabotegravir injections are more acceptable than lenacapavir injections following a single dose: results from CLARITY, a randomized crossover study of long-acting injectable antiretrovirals. Presented at: 20th European AIDS Conference; October 15\u201318, 2025; Paris, France.","DOI":"10.1007\/s12325-026-03703-3"},{"key":"3591_CR29","unstructured":"Kelley CF. Update on lenacapavir for PrEP: results from the interim analysis of PURPOSE 1 and PURPOSE 2. Presented at: IDWeek 2024; October 16\u201319, 2024; Los Angeles, CA."},{"issue":"2","key":"3591_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jmahp12020006","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, Fran\u00e7ois C, Boyer L, Laram\u00e9e P. Methods for indirect treatment comparison: results from a systematic literature review. J Mark Access Health Policy. 2024;12(2):58\u201380.","journal-title":"J Mark Access Health Policy"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03591-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:16:18Z","timestamp":1785518178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03591-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3591"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03591-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Neil Hawkins and Juliette Thompson have received consulting fees from ViiV Healthcare. Aniruddha Hazra has contracts for clinical research unrelated to this work from Gilead and has received consulting fees from Abbott Technologies, Gilead, and ViiV Healthcare. Marisa Brizzi has received payment or honoraria for speakers bureaus from Gilead and ViiV Healthcare and participated on an advisory board for Gilead, Merck, and ViiV Healthcare. Richard Grove is an employee of GSK and holds stock in GSK. Marius Sieverding has no conflicts to disclose. Piotr Budnik is an employee of ViiV Healthcare and owns stock in GSK and Haleon. Jenny Scherzer and Natalya Danchenko are employees of ViiV Healthcare and may own stock in GSK. Sarah-Jane Anderson is an employee of GSK and owns stock in GSK and Haleon. Laure Dupont-Benjamin is an employee of ViiV Healthcare; owns stock in AbbVi.e., GSK, and Haleon; and is receiving consulting fees from the International Union Against Tuberculosis and Lung Disease.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}